跳至主要内容
临床试验/NCT04333004
NCT04333004Unknown1 期

Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy

Xiaorong Dong0 个研究点目标入组 40 人开始时间: 2020年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
发起方
入组人数
40
主要终点
diversity of gut microbiota

研究概览

简要总结

Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • non-small cell lung cancer patients with less than brain metastases Patients must have received at least the first-line anti-tumor treatment, and the front-line treatment must include chemotherapy or targeted treatment with a platinum containing combination scheme, but not anti-PD-1 / L1 treatment Patients who have not received intracranial local treatment before

排除标准

  • Patients who toke major surgery within 4 weeks prior to enrollment or had ununited wounds Patients with hemorrhage in intracranial metastasis

研究组 & 干预措施

Pembrolizumab Combined With Chemotherapy

Experimental

干预措施: Pembrolizumab Combined With Chemotherapy (Drug)

结局指标

主要结局

diversity of gut microbiota

时间窗: 1 year

Species and abundance of gut microbiota

次要结局

未报告次要终点

研究者

发起方
Xiaorong Dong
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Xiaorong Dong

Professor

Wuhan Union Hospital, China

相似试验